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Abstract
Purpose: Overactivation of TGF-b signaling is observed in
myelodysplastic syndromes (MDS) and is associated with
dysplastic hematopoietic differentiation. Galunisertib, a
first-in-class oral inhibitor of the TGF-b receptor type 1 kinase
(ALK5) has shown effectiveness in preclinical models of MDS
andacceptable toxicity inphase I studies of solidmalignancies.
Patients and Methods: A phase II multicenter study of
galunisertib was conducted in patients with very low-, low-,
or intermediate-risk MDS by the Revised International Prog-
nostic Scoring System criteria with hemoglobin  10.0 g/dL.
Patients received oral galunisertib 150 mg twice daily for
14 days on/14 days off.
Results: Ten of 41 evaluable patients (24.4%; 95% confi-
dence interval, 12.4–40.3) achieved hematologic improve-
ment erythroid response by International Working Group
(IWG) 2006 criteria. A total of 18 of 41 patients (43.9%)
achieved erythroid response as per IWG 2000 criteria. Nine of
28 (32.1%) of transfusion-dependent patients had hemato-
logic improvement. A total of 18 of 41 (44%) patients had a
significant reduction in fatigue. Overall median duration of
response was 90 days in all patients. Rigorous stem and
progenitor flow cytometry showed that patients with an early
stem cell differentiation block were more likely to respond to
galunisertib. The most common treatment-emergent adverse
events were grade 1 or 2 in 20 (49%) of 41 patients, including
any-grade fatigue (8/41, 20%), diarrhea (7/41, 17%), pyrexia
(5/41, 12%), and vomiting (5/41, 12%).
Conclusions: In summary, galunisertib treatment has an
acceptable safety profile and was associated with hematologic
improvements in lower- and intermediate-risk MDS, with
responses in heavily transfusion-dependent patients and in
those with signs of an early stem cell differentiation block.
Introduction
Myelodysplastic syndromes (MDS) are a group of hematopoi-
etic stem cell neoplasms that occur predominantly in elderly
adults; these patients present with bone marrow failure and
resultant cytopenias, and may progress to acute leukemia (1).
Optimal evaluation of patients involves integration of morpho-
logic [e.g., according to World Health Organization (WHO)
criteria; ref. 2)], cytogenetic, and molecular characterization to
facilitate diagnosis and prognostic stratification via the Revised
International Prognostic Scoring System (IPSS-R) for MDS.
Patients with MDS in higher-risk IPSS-R categories have shorter
overall survival (3) and those in lower-risk categories, although
endowedwith longer life expectancy, will suffer cytopenia-related
events, including fatigue, bleeding, and infection (4).
Symptomatic anemia, which is the most frequent cytopenia
exhibited bypatientswith lower-riskMDS,maybe reduced via red
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blood cell transfusions or erythropoiesis-stimulating agents (ESA;
ref. 5). Chronic red blood cell transfusions, however, are associ-
ated with fluctuating levels of hemoglobin, iron overload, and
dependence on hospitals and caregivers (5). Among ESAs, eryth-
ropoietin alpha has been recently approved for treatment of
symptomatic anemia and yields a response in up to 50% of cases.
Although ESAs are a first-line therapeutic option, response is
usually transient (20–24 months) and is less likely for patients
with transfusion dependency, very high serum erythropoietin
levels (e.g., >500 U/L), and long duration of disease (5, 6).
Lenalidomide is approved to treat patients with lower-risk MDS
with chromosome 5q deletion, which is present in 16%–28% of
patients, and has been shown to provide transfusion indepen-
dence in 56%–67% (7, 8) of this group, whereas it has lower
efficacy in patients without 5q deletion (6). For these reasons, a
number of agents have been investigated for the treatment of
patients with low- to intermediate-risk MDS and clinically sig-
nificant anemia.
Preclinical studies have shown that the TGF-b pathway is
activated in MDS stem and progenitor cells, and causes a block
in differentiation of stem cells into committed progenitors (9).
SMAD7, a negative regulator of TGF-b signaling, is decreased in
MDS stemandprogenitor cells, resulting inupregulationof TGF-b
signaling and subsequent suppression of hematopoiesis (10).
Galunisertib is a first-in-class oral selective inhibitor of TGF-b
receptor I kinase (ALK5) that inhibits SMAD2/3 activation and
stimulates hematopoiesis in primary MDS cell cultures and in
murine models of MDS, and has an acceptable safety profile in
phase I studies (10–12). Furthermore, galunisertib is hypothe-
sized to relieve the early stem cell differentiation block seen in
some cases of MDS. In contrast, ALK1 inhibitors like luspatercept
and sotatercept target a different TGF-b signaling pathway
mediated by GDF and activin ligands and restore late stages of
hematopoiesis (13, 14). The primary aim of this study was to
estimate the rate of hematologic improvement (15) in patients
with IPSS-R very low-, low-, and intermediate-risk MDS treated
with galunisertib.
Patients and Methods
Study design and participants
This study was designed as a prospective, multicenter, global,
phase II/III study of galunisertib in patients with IPSS-R very low-,
low-, and intermediate-risk MDS. Phase II was conducted at six
centers inGermany, three centers in Italy, andfive centers in Spain.
Provided galunisertib showed hematologic improvement in at
least 50% of treated patients, the study design (Supplementary
Fig. S1) anticipated initiation of a randomized phase III study
after approval from regulatory authorities.
A sample size of 40 was calculated for the phase II portion to
provide 96.5% power and to control type I error at a one-sided
0.025 level of significance for a null hypothesis of a hematologic
improvement ratewith galunisertib of no higher than 20%and an
alternative hypothesis that the rate would be at least 50%.
The study population consisted of patients with a confirmed
MDS diagnosis (WHOcriteria; ref. 16) aged at least 18 years in the
IPSS-R very low- to intermediate-risk groups at screening, and
who had anemia with baseline hemoglobin of 10.0 g/dL or
less (average of two baseline measurements and transfusion free
for at least 1 week) with or without red blood cell transfusion
dependence (at least four units administered within 8 weeks
before enrollment), according to International Working
Group (IWG) definition. Patients with a WHO diagnosis of
nonproliferative MDS/myeloproliferative neoplasms (white
blood cells < 13,000/mL) also were eligible. Patients with MDS
with 5q deletions were only allowed if lenalidomide treatment
did not produce a response or was not tolerated.
An Eastern Cooperative Oncology Group (ECOG) scale score
of two or less and adequate liver and kidney function were
required, and participants must have discontinued all disease-
modifying MDS therapy for 28 days prior to treatment initiation
with the exception of transfusions and supportive care measures.
Patients who presented with moderate or severe cardiovascular
disease, received ESAs within 28 days of enrollment, or had a
history of acute myeloid leukemia were excluded.
This studywas conducted in accordancewith theDeclaration of
Helsinki and Council for International Organizations of Medical
Sciences International Ethical Guidelines, and ethical approval
was obtained from the ethics review board at each study site.
All participants provided written informed consent prior to
enrollment.
Procedures
Phase II participants received oral open-label galunisertib
150 mg (Eli Lilly and Company) twice daily (Supplementary
Fig. S1) for 14 days in a 28-day cycle. A cohort of three patients
was planned to receive 80 mg twice daily according to the same
intermittent dosing regimen for comparative pharmacokinetic
analysis. All patients were to receive six treatment cycles or fewer
unless they met one or more discontinuation criteria prior to
completing six cycles. Assessments included hematologic tests
(weekly), plasma cytokine/chemokine and TGF-b1 (day 1 and 15
of each cycle) measurements, and bone marrow biopsy, and
aspirate (baseline and every three cycles). All patients were fol-
lowed for 12 months.
Outcomes
The phase II primary endpoint was the rate of hematologic
improvement according to IWG 2006 criteria (15). Erythroid
response was defined by reduction of red blood cell transfusions
by at least four units or a hemoglobin increase (in patients with
less than four units in the previous 8 weeks) of at least 1.5 g/dL,
with either lasting at least 8 weeks. Key secondary objectives
included progression-free survival (PFS), change in bone marrow
Translational Relevance
Galunisertib is a first-in-class oral inhibitor of the TGF-b
receptor type 1 kinase (ALK5) that has shown effectiveness in
preclinical models of myelodysplastic syndromes (MDS).
Galunisertib was tested in a phase II multicenter study in
patients with very low-, low-, or intermediate-risk MDS and
led to erythroid hematologic improvements, specifically in
transfusion-dependent patients without any major toxicities.
Rigorous stem and progenitor flow cytometry showed that
patientswith an early stemcell differentiationblockweremore
likely to respond to galunisertib. These studies show clinical
activity of TGF-b pathway inhibitors in MDS and can poten-
tially lead to further studies with newer dosing regimens as
well as other inhibitors of this pathway.
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fibrosis, time to best hematologic improvement, and duration of
best hematologic improvement. Additional assessments included
safety and pharmacokinetics. The exploratory objectives were to
identify biomarker subsets in bone marrow cells and associated
responses and to evaluate relationships between genetic molec-
ular markers and RNA expression as predictors of response. In an
ad hoc analysis, estimated rate of hematologic improvement was
calculated according to IWG 2000 criteria, which provides two
levels of erythroid response, either of whichmust be sustained for
at least 8weeks:major (transfusion independence or hemoglobin
increase of >2 g/dL) and minor (50% transfusion reduction or
hemoglobin increase of 1–2 g/dL; ref. 17).
Safety measurements included treatment-emergent adverse
events, laboratory analyses, vital signs andphysical examinations,
hospitalizations, and blood transfusions. Cardiac safety was
assessed by echocardiography/Doppler and serial measurements
of brain natriuretic peptide (BNP) and troponin I. Treatment-
emergent adverse events were measured using the NCI Common
Terminology Criteria for Adverse Events (18).
The Brief Fatigue Inventory is a nine-item patient-reported
instrument developed to assess severity of fatigue and its impact
on quality of life with scale ratings of 0–10 (19). A fatigue
response was prespecified as a 30% reduction from baseline. The
inventorywas administered at the screening visit, on day 1 of each
cycle, and at the final visit.
To evaluate the goal of decreased bone marrow fibrosis with
treatment, change in bone marrow fibrosis from baseline was
assessed on day 15 of every third cycle through 12 months, and
then every 6 months as long as the patient remained in active
follow-up.
Statistical analysis
All patients who received at least one dose of galunisertib were
included in the efficacy and safety analyses, and in the pharma-
cokinetic analyses provided they had evaluable samples. The
hematologic improvement rate was calculated as the proportion
of all patients who received treatment and achieved hematologic
improvement for at least 8 weeks.
Data on dosing, plasma concentration versus time, and patient
characteristics were pooled and analyzed using a population
pharmacokinetics analysis approach, and nonlinear mixed-
effect modeling was used to estimate the population pharmaco-
kinetics parameters of galunisertib. Change in bone marrow
fibrosis was assessed using a mixed-effect model repeated mea-
sures analysis.
Biomarker analysis
Mutational analysis. Patient bone marrow or blood samples were
used for targeted sequencing of 40 recurrently mutated genes at
500 coverage (Genoptix). Clinically significant mutations were
identified and variant allele frequency was calculated as described
previously (20).
Stem and progenitor analysis. Mononuclear cells were isolated
fromperipheral blood samples by density gradient centrifugation
at baseline and up to cycle 3, and subjected to immunomagnetic
enrichment of CD34þ cells (Miltenyi Biotec).When samples were
available, later cycles were also assessed to determine changes in
lineages. CD34þ cells were stained with PE-Cy5 (Tricolor)-
conjugatedmAbs against lineage antigens (CD2,CD3,CD4,CD7,
CD10, CD11b, CD14, CD15, CD19, CD20, CD56, and glyco-
phorin A; BD Biosciences) and fluorochrome-conjugated anti-
bodies against CD34, CD38, CD90, CD45RA, and CD123
(eBioscience). Cells were analyzed and sorted on a Becton Dick-
inson FACSAria II equipped with four lasers (407, 488, 561/568,
and 633/647-nm). We distinguished and sorted hematopoietic
stem cells (HSC; Lin, CD34þ, and CD38) and progenitors
(Lin, CD34þ, and CD38þ), as performed previously (21).
This study is registered with ClinicalTrials.gov, number
NCT02008318.
Role of the funding source
The funder provided the study drug and collaborated with
investigators on the study design, protocol, data collection, anal-
ysis, interpretation, and writing and preparation of this article. V.
Santini prepared the first draft in collaboration with the study
funder and other coauthors. Authors had access to the study data
and all authors approved submission for publication.
Data sharing statement
The study protocol (redacted) may be found in a Supplemen-
tary Data available with the online version of this article. Lilly
provides access to all individual participant data collected during
the trial, after anonymization, with the exception of pharmaco-
kinetic or genetic data.Data are available to request 6months after
the indication studied has been approved in theUnited States and
European Union and after primary publication acceptance,
whichever is later. No expiration date of data requests is currently
set once data are made available. Access is provided after a
proposal has been approved by an independent review commit-
tee identified for this purpose and after receipt of a signed data
sharing agreement. Data and documents, including the study
protocol, statistical analysis plan, clinical study report, blank, or
annotated case report forms, will be provided in a secure data
sharing environment for up to 2 years per proposal. For details on
submitting a request, see the instructions provided at www.
clinicalstudydatarequest.com.
Results
Study participants and efficacy measures
From January 9, 2014, to September 3, 2015, 41 participants
were enrolled in the 150-mg twice-daily cohort and two in the
80-mg twice-daily cohort; all received at least one dose and were
available for evaluation (Supplementary Fig. S2). Themedian age
and gender distribution of the participants (Table 1) were repre-
sentative of MDS patient population demographics.
For the efficacy analyses, 28 of 41 (68.3%) patients were
transfusion dependent at baseline, needing at least four units in
the 8 weeks prior to study initiation (Table 2; Fig. 1A). Nine
(32.1%) of these patients achieved a clinically significant trans-
fusion reduction of 4 units of packed red blood cells over 8 or
more weeks. Among patients who obtained significant transfu-
sion reduction, one also achieved platelet response (average
platelet count of <100  109/L over 8 weeks at baseline, and an
increase of30 109/L lasting at least 8 weeks during the study).
Erythroid response (HI-E) was observed in 10 of 41 patients
(24.4%; Table 2). The median duration of galunisertib treatment
for erythroid responders (n ¼ 10) was 22 weeks. Figure 1A
demonstrates the maximum change in transfusion requirements
inpreviously transfusedpatients. Figure 1B shows thedistribution
of change in hemoglobin levels from baseline. One patient who
Santini et al.
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was transfusion independent at baseline achieved erythroid
hematologic improvement measured by an increase in hemoglo-
bin of at least 1.5 g/dL from baseline formore than 8weeks, had a
durable response of 462 days at time of data cutoff, and did not
require transfusions pre- and posttreatment. The hemoglobin
level for this patient at baseline was 9.7 g/dL and rose to a peak
of 14.1 g/dL on day 547 (Supplementary Fig. S3). No patients
achieved neutrophil response.
The HI-E was paralleled by improvement of fatigue as deter-
mined by the change in score of the Brief Fatigue Inventory
(Fig. 1C). Results from the Brief Fatigue Inventory analysis
revealed the two patients who received galunisertib 80 mg twice
daily achieved no change in fatigue compared with baseline.
However, in patients who received galunisertib 150 mg twice
daily for six cycles, 18 of the 41 patients (44%) were observed to
have a 30% reduction frombaseline in the Brief Fatigue Inventory
mean score at cycle 6 (Fig. 1C). Of the 10 patients with HI-E, six
patients also had an improvement in the Brief Fatigue Inventory
score.
In an ad hoc assessment of responses by IWG response criteria
2000, 18 of 41 patients (43.9%) achieved erythroid response,
with nine (22.0%) of 41 patients each meeting major and minor
response thresholds (Supplementary Table S1). Eight of the 18
patients qualified for response under IWG 2000 but not for IWG
2006, including two patients who achieved major response by
transfusion independence for at least 8weeks, threewho achieved
minor response by transfusion reduction 50% for at least
8 weeks, and three who achieved minor response by hemoglobin
increase.
Biomarker studies (plasma TGF-b1 levels, cytogenetics,
mutational status, stem cell and bone marrow studies, and
lymphocyte subsets)
In addition to the clinical response assessments, we observed
that plasma TGF-b1 levels were reduced by more than 20% from
baseline in thefirst six cycles in 14of 15patients (93.3%)whohad
baseline levels of more than 2,000 ng/L. We noted that seven
patients withHI-E per IWG2006 also had a significant decrease in
plasmaTGF-b1 levels. This reductionoccurred about 90–100days
after starting galunisertib therapy (Supplementary Fig. S4).
We also investigated whether specific baseline biological char-
acteristics could help identify patients who may benefit from
receiving anALK5 inhibitor. This investigationwas done based on
available samples and the analysis was performed on both in
relationship to all available samples and based on the IWG 2006
and 2000 response criteria. We observed that six patients with
normal cytogenetics and one patient with multiple cytogenetic
abnormalities experienced HI-E (Table 3). Analyses of HI-E
per WHO MDS subtype showed that nine of the 10 responders
had refractory cytopenia with multilineage dysplasia (RCMD)
and one had refractory anemia with ringed sideroblasts
(RARS; Table 3). There was no correlation between response and
endogenous erythropoietin levels, and endogenous EPO levels
were less than or equal to 500 U/L in 73% (30/41) of the cases
(Table 3).
Because MDS is characterized by differentiation arrest, and to
determine whether galunisertib had an effect on stem cell
modulation, we performed analysis of stem and progenitor
cells in a subset (15/41) of patient samples. Patients with HI-E
had a pronounced stem cell differentiation arrest with a
higher baseline proportion of stem cells [Lineage (Lin) and
CD33/CD34þ/CD38 cells] in peripheral blood (n ¼ 5) when
compared with nonresponders (n ¼ 10; Fig. 2A). Furthermore,
serial samples available in one responder patient showed an
increase in differentiation of stem cells to progenitors with
treatment (Fig. 2B and C).
We further evaluated the mutational status of 28 MDS cases
with available DNA by targeted deep sequencing of MDS recur-
rently mutated genes. In the 150-mg twice-daily group, the most




daily (N ¼ 41)
80 mg twice daily
(N ¼ 2)
Age, years, median (IQR) 71 (66–76) 63 (55–70)
Sex
Male 26 (63%) 1 (50%)
ECOG performance status
0 22 (54%) 0
1 19 (46%) 2 (100%)
IPSS-R prognostic risk
Very low (1.5) 2 (5%) 0
Low (>1.5–3) 30 (73%) 1 (50%)
Intermediate (>3–4.5) 9 (22%) 1 (50%)
Classification of MDS, WHO 2008
Unclassified 3 (7%) 1 (50%)
RARS 8 (20%) 0
RCMD 28 (68%) 0
Refractory cytopenia with
unilineage dysplasia
2 (5%) 1 (50%)
Cytogenetic
Normal 23 (56%) 0
Abnormal 7 (17%) 2 (100%)
NA 11 (27%) 0
Bone marrow ringed sideroblasts
(by central laboratory)a
Available bone marrow, n 27 (66%) 1 (50%)
0% 11/27 (41%) 0
>5% 16/27 (59%) 1/1 (100%)
NA 14 (34%) 1 (50%)
SFB31 gene mutation (by central
laboratory)
Evaluable samples 28 (68%) 1 (50%)
SF3B1 17/28 (61%) 1/1 (100%)
No SF3B1 mutation 11/28 (39%) 0
NA 13 (32%) 0
Erythropoietin
<200 U/L 23 (56%) 2 (100%)
200–500 U/L 7 (17%) 0
>500 U/L 10 (24%) 0
NA 1 (2%) 0
Prior therapies – classb










Differentiating factor 3 (7%)
Hypomethylating agents 2 (5%)
Steroids 2 (5%)
Iron chelator 1 (2%)
NOTE: Data are n (%) except where indicated otherwise. Where baseline values
are missing, the percentage is of the patients with baseline values.
Abbreviation: NA, not available.
aPrussian Blue stain.
bPatients may be included in more than one category.
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Table 2. Hematologic improvement in patients treated with galunisertib, 150 mg twice daily, IWG 2006 criteria (prespecified assessment)
Baseline transfusion
need Number of patients
HI (Tf or Hb increase)
during any 8 weeks




4 units 28 9/28 (32.1%) 89 (75–95) 6/28 (21.4%)
1–3 units 2 0 2/2 (100%)
0 units 11 1/11 (9.1%) 462a 10/11 (90.9%)b
Total 41 10/41 (24.4%) 90 (75–103) 18/41 (43.9%)
NOTE: Data are n (%) except where indicated otherwise.
Abbreviations: Hb, hemoglobin; HI, hematologic improvement; Tf, transfusion; TI, transfusion independent.
aDuration of response in only one patient no range available.
bRemained transfusion free.
Figure 1.
Response assessments for patients receiving
galunisertib. Changes in transfusion burden (A), in
hemoglobin levels (B), and by achieving prespecified
response on the Brief Fatigue Inventory (C). A,Maximum
percentage change in red blood cell transfusion burden
in previously transfused patients (N¼ 32). Patients are
differentiated by baseline transfusion requirements of
<4 units in any 8-week period (blue) or4 units in any
8-week period (green) before treatment initiation. Note:
two patients who were transfusion dependent at
baseline had no change in transfusion requirements.
Four patients that were transfusion dependent at
baseline had no postbaseline records and are
represented on the graph as no change in transfusion
burden. Eleven patients not shown on this graph were
transfusion independent at baseline (three patients who
were transfusion independent at baseline received
transfusions posttreatment and the minimum in any
8-week period for two of these was zero transfusions;
the other patient required ongoing transfusions).
B, Distribution of change in hemoglobin from baseline
for patients. Number of patients with available
measurements at each timepoint is shown under the
graph. N¼ 35 (all patients who received transfusions).
C, Percentage of patients achieving prespecified
response on the Brief Fatigue Inventory (improvement
of 30% reduction from baseline score). Data were
available from all patients at baseline and in each of the
first six cycles. BID, twice daily.
Santini et al.
Clin Cancer Res; 25(23) December 1, 2019 Clinical Cancer Research6980
on December 18, 2020. © 2019 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst September 3, 2019; DOI: 10.1158/1078-0432.CCR-19-1338 
frequently mutated gene was SF3B1 [mutated in 17/28 samples
(61%); Supplementary Fig. S5]. HI-E was observed in six of 17
patientswith a SF3B1mutation and in three of 11patientswithno
SF3B1 mutation. Eleven patients with a SF3B1 mutation [11/17
(65%)] did not experience HI-E. Interestingly, all four of the
patients with an isolated mutation in SF3B1 without any other
comutations responded to galunisertib and achieved a HI-E
response. Given the small number of patients evaluated, other
genemutations (i.e., TET2 and ASXL1) could not be evaluated for
correlation with response.
Themedian PFS in patients with an IPSS-R very low- or low-risk
(N ¼ 33) was not reached (95% confidence interval, 97 weeks–
not reached; Supplementary Fig. S6). PFS was better among the
patients who achieved HI-E compared with those who did not
achieve HI-E; however, the difference in PFS was not statistically
significant.
Bone marrow fibrosis was reported in 11 of the 31 patients
(35%) who had both baseline and postbaseline assessments.
Three patients had bone marrow fibrosis improvements (two
frommoderate to negative, one frommild to negative), although
none of these patients had HI-E. Of the 10 patients who achieved
HI-E, four had no change in bone marrow fibrosis grading, four
could not be assessed (i.e., did not have a baseline and postbase-
line assessment), and two had transient increases that subse-
quently decreased.
Because natural killer (NK) and T-cell subsets can produce
TGF-b1, T-cell subsets were measured before and during treat-
ment. While there was no clear evidence of a change in any of
the subsets, it appeared that NK cells increased in numbers
during treatment with galunisertib (Supplementary Fig. S7).
Eight patients showed progressive increases of NK cell counts
over time not associated with erythroid response to galunisertib
Pharmacokinetic profile
The pharmacokinetic profile was the same as in previous
studies (22), with no unexpected variations. Dose-normalized
steady-state observations for cycle 1 (Supplementary Fig. S8)
showed that galunisertib was rapidly absorbed and had
Table 3. Hematologic improvement (IWG 2006 and IWG 2000) by available baseline disease characteristics (150-mg twice-daily group) and adjusted for available
samples
Disease characteristic Number of available samples IWG 2006 (see Table 2) IWG 2000a (see Table 2)
Cytogenetic abnormalities (where
more than 20 metaphases analyzed)
N1 ¼ 30 Responder N ¼ 10 Nonresponder N ¼ 31 Responder N ¼ 18 Nonresponder N ¼ 23
Normal 23/30 (77%) 6/23 (26%) 17/23 (74%) 13/23 (57%) 10/23 (43%)
[% by response] [6/10 (60%)] [17/31 (55%)] [13/18 (72%)] [10/23 (43%)]
Abnormal 7/30 (23%) 1/7 (14%) 6/7 (86%) 1/7 (14%) 6/7 (86%)
[% by response] [1/10 (10%)] [6/31 (19%)] [1/18 (6%)] [6/23 (26%)]
Responder Nonresponder Responder Nonresponder
MDS subtypes N1 ¼ 41 N ¼ 10 N ¼ 31 N ¼ 18 N ¼ 23
UN 3/41 (7%) 0/3 (0%) 3/3 (100%) 0/3 (0%) 3/3 (100%)
[% by response] [0/10 (0%)] [3/31 (10%)] [0/18 (0%)] [3/23 (13%)]
RARS 8/41 (20%) 1/8 (13%) 7/8 (88%) 2/8 (25%) 6/8 (75%)
[% by response] [1/10 (10%)] [7/31 (26%)] [2/18 (11%)] [6/23 (26%)]
RCMD 28/41 (68%) 9/28 (32%) 19/28 (68%) 15/28 (54%) 13/28 (46%)
[% by response] [9/10 (90%)] [19/31 (61%)] [15/18 (83%)] [13/23 (57%)]
RCUD 2/41 (5%) 0/2 (0%) 2/2 (100%) 1/2 (50%) 1/2 (50%)
[% by response] [0/10 (0%)] [2/31 (6%)] [1/18 (6%)] [1/23 (4%)]
Responder Nonresponder Responder Nonresponder
Gene mutation N1 ¼ 28 N ¼ 10 N ¼ 31 N ¼ 18 N ¼ 23
SF3B1 17/28 (61%) 6/17 (35%) 11/17 (65%) 11/17 (65%) 6/17 (35%)
[% by response] [6/10 (60%)] [11/31 (35%)] [11/18 (61%)] [6/23 (26%)]
No SF3B1 11/28 (39%) 3/11 (27%) 8/11 (73%) 4/11 (36%) 7/11 (64%)
[% by response] [3/10 (30%)] [8/31 (26%)] [4/18 (22%)] [7/23 (30%)]
Responder Nonresponder Responder Nonresponder
Bone marrow ringed- sideroblastsb N1 ¼ 27 N ¼ 10 N ¼ 31 N ¼ 18 N ¼ 23
0% 11/27 (41%) 2/11 (18%) 9/11 (82%) 5/11 (45%) 6/11 (55%)
[% by response] [2/10 (20%)] [9/31 (29%)] [5/18 (28%)] [6/23 (26%)]
>5% 16/27 (59%) 4/16 (25%) 12/16 (75%) 5/16 (31%) 11/16 (69%)
[% by response] [4/10 (40%)] [12/31 (39%)] [5/18 (28%)] [11/23 (48%)]
Responder Nonresponder Responder Nonresponder
Serum erythropoietin (U/L) N1 ¼ 41 N ¼ 10 N ¼ 31 N ¼ 18 N ¼ 23
NA 1/41 (2%) 1/1 (100%) 0/1 (0%) 1 (100%) 0/1 (0%)
[% by response] [1/10 (10%)] [0/31 (0%)] [1/18 (6%)] [0/23 (0%)]
<200 23/41 (56%) 6/23 (26%) 17/23 (74%) 13/23 (57%) 10/23 (43%)
[% by response] [6/10 (60%)] [17/31 (55%)] [13/18 (72%)] [10/23 (43%)]
200–500 7/41 (17%) 1/7 (14%) 6/7 (86%) 2/7 (29%) 5/7 (71%)
[% by response] [1/10 (10%)] [6/31 (19%)] [2/18 (11%)] [5/23 (22%)]
>500 10/41 (24%) 2/10 (20%) 8/10 (80%) 2/10 (20%) 8/10 (80%)
[% by response] [2/10 (20%)] [8/31 (26%)] [2/18 (11%)] [8/23 (35%)]
NOTE: Data are n (%) except where indicated otherwise. Percentages are calculated on the basis of number of nonmissing values in each disease category. Where
responders do not total 10 for IWG 2006 or 18 for IWG 2000 criteria, patients are missing baseline values.
Abbreviations: N, number of patients dosed; N1, number of patients with sample; n, number of patients in category; NA, not available; UN, unclassified; RCUD,
refractory cytopenia with unilineage dysplasia.
aMajor and minor transfusion and Hb responses combined
bAs determined by BM Prussian Blue Stain.
Galunisertib in Myelodysplastic Syndromes
www.aacrjournals.org Clin Cancer Res; 25(23) December 1, 2019 6981
on December 18, 2020. © 2019 American Association for Cancer Research.clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst September 3, 2019; DOI: 10.1158/1078-0432.CCR-19-1338 
subsequent biphasic disposition. The observed plasma concen-
trations from this study were comparable with concentration
observations in other solid tumor studies (23, 24). Galunisertib
plasma concentrations in responders were similar to those
observed in patients with no response.
Safety evaluation
Adverse events.Galunisertib 150mg twice daily was well tolerated
(Table 4; Supplementary Table S2). One patient had to interrupt
treatment for a study treatment-related adverse event (retroper-
itoneal hemorrhage). The most common events in 41 patients
were grade 1–3, particularly diarrhea (n ¼ 7, 17%) and fatigue
(n¼ 8, 20%). Grade 3 and 4 toxicity was observed in eight (20%)
and four (10%) of 41 patients, respectively, most of which were
nonhematologic. No apparent cardiac toxicity was observed
during the comprehensive cardiac monitoring. There were three
patients with grade 3 cardiac failure, all of whom had preexisting
cardiac conditions, and twowith an aortic dilatation byCT scan at
baseline; none of the cardiac findings prevented the patients from
maintaining therapy with galunisertib. Consistent with the clin-
ical observations, BNP levels remained unchanged over the treat-
ment time (Supplementary Fig. S9).
Discussion
Orally administered galunisertib is a first-in-class small-
molecule inhibitor of the TGF-b kinase that has shown a
manageable safety profile in solid tumor trials (12, 25, 26).
On the basis of the previous clinical experiences, we investi-
gated the role of galunisertib in patients with MDS (12, 25, 26).
Recent studies with ACVR2B/ALK1/2 inhibitors (23, 24) sug-
gest that targeting family members of the TGF-b signaling
pathway may result in improvements in erythropoiesis in MDS.
In contrast to the ALK1/2 inhibitors (27), galunisertib blocks
the signaling mediated via ALK5, thus possibly inducing
improvement of early bone marrow progenitor maturation as
well as reducing inflammation (10).
In this study, galunisertib reduced transfusion requirements
(Fig. 1A), including in patients with prior high transfusion
requirements. We compared the erythroid response based on
IWG 2006 [10/41 (24.4%) patients] with that according to IWG
2000 criteria [18/41 (43.9%) patients]. In the latter evaluation,
minor and major erythroid improvements were considered.
In our study, 28 of 41 patients (68.3%) treated with galunisertib
150 mg twice daily could be evaluated for erythroid response
in terms of reduction in red blood cell transfusions
(receiving 4 U/8 weeks), and their response rate was 32.1%
(9/28 patients). Most patients remained on treatment for about
6 months, with stable HI-E in some cases and evident improve-
ments in fatigue. Whether prolonged administration of galuni-
sertib can achieve higher rates of HI-E has not been explored.
On the basis of the observed reduction in TGF-b1 levels
during galunisertib treatment in patients with baseline levels
>2,000 ng/L, and the known relevance of such elevated
Figure 2.
Stem cell differentiation block (CD34þ, CD38, Lin, and CD33) is associated with response to galunisertib. A, A total of 15 patients that included five
responders and 10 nonresponders with evaluable samples were analyzed by multiparameter flow cytometry for stem and progenitor assessment. Patients who
responded to galunisertib had an increased proportion of hematopoietic stem cells (HSCs) in their peripheral blood (n¼ 5) when compared with nonresponders
(n¼ 10; meansþ SEM; t test;  , P¼ 0.006). B, Representative FACS plots from one responder and one nonresponder are shown. Lin, CD33, CD34þ, and
CD38 HSCs and Lin, CD33, CD34þ, and CD38þ progenitors are shown. C, Serial samples from one responder to galunisertib shows decreased HSC
percentage and increased progenitor differentiation in posttreatment sample.
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levels for cancer progression (28), we interpret the reduction in
TGF-b1 levels as a signal of an effective drug treatment as previ-
ously reported in solid tumors (29).
Although the number of cases is limited, it appears that patients
with normal cytogenetics and with a WHO diagnosis of RCMD
were more likely to obtain erythroid improvement. In addition,
we observed that patients with isolated mutations in SF3B1
without other comutations all responded to galunisertib. Of note,
the WHO 2008 classification eliminated the subtype RCMD-RS
present in WHO 2001, and may account for the responses with
RCMD and SF3B1mutations we saw in this study. These observa-
tions canbe followed up in future larger studies (27) and suggest a
distinct modulation of TGF-b signaling by galunisertib.
To further understand the characteristics of the patients with
MDS in whom the ALK5 inhibition may have a pharmacologic
effect, we determined the size of the stem cell population in some
patients prior to treatment. We observed that patients with MDS
with a pronounced stem cell differentiation block at baseline,
characterized by a higher proportion of stem cells (Lin, CD33,
CD34þ, and CD38) in peripheral blood, obtained HI-E. These
findings suggest that early progenitor differentiation block could
originate from increased TGF-b signaling and/or greater SMAD7
deficit, and therefore could be responsive to ALK5 inhibition. This
is different from what was observed in clinical studies with
luspatercept and sotatercept, in which apparently late stage
hematopoiesis was selectively restored (23, 24). It is possible
that TGF-b acts on early stages, while GDF11 and other ACVR2B
ligands act as inhibitory ligands on late stages of erythropoiesis.
These findings also show that with advances in purified FACS
analytical capabilities, cellular biomarkers can be incorporated in
future trials with agents that act at the level of MDS stem cells.
To our knowledge, this is the first phase II study of patientswith
IPSS-R lower-risk MDSs treated with the oral drug galunisertib.
Galunisertib demonstrated clinical activity as determined by
reduction in fatigue and in transfusion requirements for patients
with very low-, low-, and intermediate-riskMDSs. The tolerability
profile of galunisertib in this study was consistent with previous
observations (25, 26), and was favorable compared with other
agents evaluated in patients with lower-risk MDS, with minimal
hematologic toxicity (7, 8, 30). Moreover, oral administration is
relevant for quality of life issues in patients with long-surviving,
transfusion-dependent MDS. Together, the improvement of
fatigue, reduction in transfusion requirements, and oral admin-
istration points to potential efficacy of ALK5 inhibition for select-
ed patients withMDS and symptomatic anemia resistant to ESAs.
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Table 4. CTCAE safety: all treatment-emergent adverse events reported in 3 patients or with any grade 3 events, regardless of causality
Galunisertib 150 mg twice daily (N ¼ 41) Maximum grade
TEAE Any grade Grade 1–2 Grade 3 Grade 4 Grade 5
Subjects with  1 TEAE 33 (80%) 20 (49%) 8 (20%) 4 (10%) 1 (2%)
Fatigue 8 (20%) 7 (17%) 1 (2%) 0 (0%) 0 (0%)
Diarrhea 7 (17%) 7 (17%) 0 (0%) 0 (0%) 0 (0%)
Pyrexia 5 (12%) 5 (12%) 0 (0%) 0 (0%) 0 (0%)
Vomiting 5 (12%) 5 (12%) 0 (0%) 0 (0%) 0 (0%)
Anemia 4 (10%) 3 (7%) 0 (0%) 1 (2%) 0 (0%)
Cardiac failure 4 (10%) 1 (2%) 3 (7%) 0 (0%) 0 (0%)
Neutrophil count decreased 3 (7%) 0 (0%) 2 (5%) 1 (2%) 0 (0%)
Respiratory failure 2 (5%) 1 (2%) 0 (0%) 0 (0%) 1 (2%)
Aortic injurya 2 (5%) 0 (0%) 1 (2%) 1 (2%) 0 (0%)
Eczema 2 (5%) 1 (2%) 0 (0%) 1 (2%) 0 (0%)
Peripheral edema 2 (5%) 1 (2%) 0 (0%) 1 (2%) 0 (0%)
Pain 2 (5%) 1 (2%) 1 (2%) 0 (0%) 0 (0%)
Platelet count decreased 2 (5%) 1 (2%) 1 (2%) 0 (0%) 0 (0%)
Retroperitoneal hemorrhage 1 (2%) 0 (0%) 0 (0%) 0 (0%) 1 (2%)
Dyspnea 1 (2%) 0 (0%) 0 (0%) 1 (2%) 0 (0%)
Cataract 1 (2%) 0 (0%) 1 (2%) 0 (0%) 0 (0%)
Crohn disease 1 (2%) 0 (0%) 1 (2%) 0 (0%) 0 (0%)
Febrile neutropenia 1 (2%) 0 (0%) 1 (2%) 0 (0%) 0 (0%)
Pleural effusion 1 (2%) 0 (0%) 1 (2%) 0 (0%) 0 (0%)
Pulmonary edema 1 (2%) 0 (0%) 1 (2%) 0 (0%) 0 (0%)
Tongue abscess 1 (2%) 0 (0%) 1 (2%) 0 (0%) 0 (0%)
White blood cell count decreased 1 (2%) 0 (0%) 1 (2%) 0 (0%) 0 (0%)
NOTE: Data are n (%) except where indicated otherwise.
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; TEAE, treatment-emergent adverse events.
aAneurysmic dilatation of the ascending aorta was identified just prior to cycle 2 with an angio CT. The angio CT was consistent with the baseline CT, which
demonstrated similar enlargement of the aorta. Baseline and repeat echocardiograms demonstrated a tortuous aortawithout aneurysmunchangedbetween the two
echocardiograms. The investigator felt that the lesion was present at baseline and that there was no relationship between the aortic finding and galunisertib.
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